NEW YORK, Dec. 22, 2017 -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Array Biopharma Inc. (NASDAQ:ARRY) from December 16, 2015 through March 17, 2017, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Array investors under the federal securities laws.
To join the Array class action, go to http://rosenlegal.com/cases-1248.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
According to the lawsuit, defendants during the Class Period made materially false and/or misleading statements and/or failed to disclose that: (1) Array’s NEMO study failed to show sufficient clinical benefit of the binimetinib NDA in use for patients with NRAS-mutant melanoma; (2) it was aware that this lack of supporting data would not be sufficient to receive FDA approval of binimetinib in use for patients with NRAS-mutual melanoma; and (3) as a result of the foregoing, Array’s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 22, 2018. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://rosenlegal.com/cases-1248.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at [email protected] or [email protected].
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Since 2014, Rosen Law Firm has been ranked #2 in the nation by Institutional Shareholder Services for the number of securities class action settlements annually obtained for investors.
-------------------------------
Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
Kevin Chan, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 34th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
[email protected]
[email protected]
www.rosenlegal.com


More U.S. Investors Join Arbitration Against South Korea Over Coupang Dispute
Petrobras Posts Record Oil Exports as Production Surge Fuels Global Expansion
CBA Shares Surge After Record Half-Year Profit as Rate Outlook Improves
ANZ Shares Hit Record High After Strong Q1 Profit and Cost-Cutting Gains
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms
Novocure Stock Surges 30% After FDA Approves Optune Pax for Pancreatic Cancer Treatment
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates
Cloudflare Forecasts Strong Revenue Growth as AI Fuels Cloud Services Demand
U.S. Commerce Department Reaches $252 Million Settlement With Applied Materials Over China Exports
Air New Zealand Cabin Crew Strike Set for February 12–13 Amid Failed Talks
AbbVie Sues HHS Over Medicare Price Controls on Botox Under Inflation Reduction Act
Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes
Instagram CEO Defends Platform in Youth Mental Health Lawsuit Over Social Media Addiction Claims
Boeing Reports Major Supply Chain Quality Improvements After Spirit AeroSystems Deal
Standard Chartered Names Peter Burrill as Interim Group CFO Following Diego De Giorgi’s Exit
Lyft Shares Slide After Weak Q1 Profit Forecast and Surprise 2025 Operating Loss
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 



